Liver diseases, including viral hepatitis, fatty liver, metabolic-associated fatty liver disease, liver cirrhosis, alcoholic liver disease, and liver neoplasms, are major global health challenges. Despite the continued development of new drugs and technologies, the prognosis of end-stage liver diseases, including advanced liver cirrhosis and liver neoplasms, remains poor. Follistatin-like protein 1 (FSTL1), an extracellular glycoprotein, is secreted by various cell types. It is a glycoprotein that belongs to the family of secreted proteins acidic and rich in cysteine (SPARC). It is also known as transforming growth factor-beta inducible TSC-36 and follistatin-related protein (FRP). FSTL1 plays a key role in cell survival, proliferation, differentiation, and migration, as well as the regulation of inflammation and immunity. Studies have demonstrated that FSTL1 significantly affects the occurrence and development of liver diseases. This article reviews the role and mechanism of FSLT1 in liver diseases.
HanHSKangGKimJSChoiBHKooSH.Regulation of glucose metabolism from a liver-centric perspective.Exp Mol Med2016;48:e218
3.
WangYSongLLiuMGeRZhouQLiuWLiRQieJZhenBWangYHeFQinJDingC.A proteomics landscape of circadian clock in mouse liver.Nat Commun2018;9:1553
4.
KangJHToitaRMurataM.Liver cell-targeted delivery of therapeutic molecules.Crit Rev Biotechnol2016;36:132–43
5.
GaoB.Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease.J Gastroenterol Hepatol2012;27:89–93
6.
SetoW-KLoY-RPawlotskyJ-MYuenM-F.Chronic hepatitis B virus infection.Lancet2018;392:2313–24
7.
ZhengRZhangSZengHWangSSunKChenRLiLWeiWHeJ.Cancer incidence and mortality in China, 2016.J Nat Cancer Center2022;2:1–9
8.
MattiottiAPrakashSBarnettPvan den HoffMJB. Follistatin-like 1 in development and human diseases.Cell Mol Life Sci2018;75:2339–54
9.
ZhouXXiaoXHuangTDuCWangSMoYMaNMurataMLiBWenWHuangGZengXZhangZ.Epigenetic inactivation of follistatin-like 1 mediates tumor immune evasion in nasopharyngeal carcinoma.Oncotarget2016;7:16433–44
10.
TanakaKValero-MuñozMWilsonRMEssickEEFowlerCTNakamuraKvan den HoffMOuchiNSamF.Follistatin like 1 regulates hypertrophy in heart failure with preserved ejection fraction.JACC Basic Transl Sci2016;1:207–21
11.
ChenWXiaJHuPZhouFChenYWuJLeiWShenZ.Follistatin-like 1 protects cardiomyoblasts from injury induced by sodium nitroprusside through modulating Akt and Smad1/5/9 signaling.Biochem Biophys Res Commun2016;469:418–23
12.
SundaramGMCommonJEGopalFESrikantaSLakshmanKLunnyDPLimTCTanavdeVLaneEBSampathP.“See-saw” expression of microRNA-198 and FSTL1 from a single transcript in wound healing.Nature2013;495:103–6
13.
ShangHLiuXGuoH.Knockdown of Fstl1 attenuates hepatic stellate cell activation through the TGF-β1/Smad3 signaling pathway.Mol Med Rep2017;16:7119–23
14.
ShibanumaMMJMitaAKurokiTNoseK. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide.Eur J Biochem1993;217:13–9
15.
LiWAlahdalMDengZLiuJZhaoZChengXChenXLiJYinJLiYWangGWangDTangKZhangJ.Molecular functions of FSTL1 in the osteoarthritis.Int Immunopharmacol2020;83:106465
16.
LiXLiLChangYNingWLiuX.Structural and functional study of FK domain of Fstl1.Protein Sci2019;28:1819–29
17.
GengYDongYYuMZhangLYanXSunJQiaoLGengHNakajimaMFuruichiTIkegawaSGaoXChenYGJiangDNingW.Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development.Proc Natl Acad Sci USA2011;108:7058–63
18.
OuchiNOshimaYOhashiKHiguchiAIkegamiCIzumiyaYWalshK.Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism.J Biol Chem2008;283:32802–11
19.
RochetteLVergelyC.“Pro-youthful” factors in the “labyrinth” of cardiac rejuvenation.Exp Gerontol2016;83:1–5
20.
HambrockHOKaufmannBMullerSHanischFGNoseKPaulssonMMaurerPHartmannU.Structural characterization of TSC-36/Flik: analysis of two charge isoforms.J Biol Chem2004;279:11727–35
21.
Lara-PezziEFelkinLEBirksEJSarathchandraPPanseKDGeorgeRHallJLYacoubMHRosenthalNBartonPJ.Expression of follistatin-related genes is altered in heart failure.Endocrinology2008;149:5822–7
22.
WideraCHorn-WichmannRKempfTBethmannKFiedlerBSharmaSLichtinghagenRLeitolfHIvandicBKatusHAGiannitsisEWollertKC.Circulating concentrations of follistatin-like 1 in healthy individuals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay.Clin Chem2009;55:1794–800
23.
ShiDLShiGRXieJDuXZYangH.MicroRNA-27a inhibits cell migration and invasion of fibroblast-like synoviocytes by targeting follistatin-like protein 1 in rheumatoid arthritis.Mol Cells2016;39:611–8
24.
MillerMEsnaultSKurtenRCKellyEABeppuADasSRosenthalPRamsdellJCroftMZurawBJarjourNHamidQBroideDH.Segmental allergen challenge increases levels of airway follistatin-like 1 in patients with asthma.J Allergy Clin Immunol2016;138:596–9
25.
LiuYHanXYuYDingYNiCLiuWHouXLiZHouJShenDYinJZhangHThompsonTCTanXCaoG.A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression.Sci Rep2016;6:26689
26.
WangHHuangSWuSYinSTangAWenW.Follistatin-like protein-1 upregulates dendritic cell-based immunity in patients with nasopharyngeal carcinoma.J Interferon Cytokine Res2017;37:494–502
27.
ChanQKNganHYIpPPLiuVWXueWCCheungAN.Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: a differential expression and functional analysis.Carcinogenesis2009;30:114–21
28.
LauMCNgKYWongTLTongMLeeTKMingXYLawSLeeNPCheungALQinYRChanKWNingWGuanXYMaS. FSTL1 promotes metastasis and chemoresistance in esophageal squamous cell carcinoma through NFκB-BMP signaling cross-talk.Cancer Res2017;77:5886–99
29.
GuCWangXLongTWangXZhongYMaYHuZLiZ.FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway.Cell Death Dis2018;9:654
30.
ReddySPBrittoRVinnakotaKAparnaHSreepathiHKThotaBKumariAShilpaBMVrindaMUmeshSSamuelCShettyMTandonAPandeyPHegdeSHegdeASBalasubramaniamAChandramouliBASantoshVKondaiahPSomasundaramKRaoMR.Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis.Clin Cancer Res2008;14: 2978–87
31.
FanNSunHWangYWangYZhangLXiaZPengLHouYShenWLiuRYinJPengY.Follistatin-like 1: a potential mediator of inflammation in obesity.Mediators Inflamm2013;2013:752519
32.
Prieto-EchagüeVLodhSColmanLBobbaNSantosLKatsanisNEscandeCZaghloulNABadanoJL.BBS4 regulates the expression and secretion of FSTL1, a protein that participates in ciliogenesis and the differentiation of 3T3-L1.Sci Rep2017;7:9765
33.
VollmannEHCaoLAmatucciAReynoldsTHamannSDalkilic-LiddleICameronTOHossbachMKauffmanKJMirFFAndersonDGNovobrantsevaTKotelianskyVKisselevaTBrennerDDuffieldJBurklyLC.Identification of novel fibrosis modifiers by in vivo siRNA silencing.Mol Ther Nucleic Acids2017;7:314–23
AcharyaCBajajJS.Chronic liver diseases and the microbiome-translating our knowledge of gut microbiota to management of chronic liver disease.Gastroenterology2021;160:556–72
36.
EslamMSarinSKWongVWFanJGKawaguchiTAhnSHZhengMHShihaGYilmazYGaniRAlamSDanYYKaoJHHamidSCuaIHChanWKPayawalDTanSSTanwandeeTAdamsLAKumarMOmataMGeorgeJ.The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Hepatol Int2020;14:889–919
37.
Mendez-SanchezNArreseMGadanoAOliveiraCPFassioEArabJPChávez-TapiaNCDirchwolfMTorreARidruejoEPinchemel-CotrimHCastellanos FernándezMIUribeMGiralaMDiaz-FerrerJRestrepoJCPadilla-MachacaMDagherLGaticaMOlaecheaBPessôaMGSilvaM.The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.Lancet Gastroenterol Hepatol2021;6:65–72
38.
ShihaGAlswatKAl KhatryMShararaAIÖrmeciNWakedIBenazzouzMAl-AliFHamedAEHamoudiWAttiaDDerbalaMSharaf-EldinMAl-BusafiSAZakySBamakhramaKIbrahimNAjlouniYSabbahMSalamaMAnushiravaniAAfredjNBarakatSHashimAFouadYSolimanR.Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.Lancet Gastroenterol Hepatol2021;6:57–64
39.
SpearmanCWDesalegnHOcamaPAwukuYAOjoOElsahharMAbdoAANdububaDAFouadYBorodoMMNg’wanasayiMAllyRElwakilR.The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD.J Hepatol2021;74:1256–8
40.
NanYAnJBaoJChenHChenYDingHDouXDuanZFanJGaoYHanTHanYHuPHuangYHuangYJiaJJiangJJiangYLiJLiJLiRLiSLiWLiYLinSLiuJLiuSLuLLuQLuoXMaXRaoHRenHRenWShangJShiLSuMWangBWangRWeiLWenZWuBWuJXinSXingHXuJYanMYangJYangJYangLYangYYuYZhangLZhangLZhangXZhangYZhangYZhaoJZhaoSZhengHZhouYZhouYZhuangHZuoWXuXQiaoL.The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.J Hepatol2021;75:454–61
41.
FouadYMGomaaAEl EtrebyRMAbdAllahMAttiaD.Editorial: the Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD) and Non-Alcoholic Fatty Liver Disease (NAFLD) debate: why the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) consensus process is not representative.Medical Science Monitor2022;28:e938066
42.
EslamMNewsomePNSarinSKAnsteeQMTargherGRomero-GomezMZelber-SagiSWai-Sun WongVDufourJFSchattenbergJMKawaguchiTArreseMValentiLShihaGTiribelliCYki-JarvinenHFanJGGronbaekHYilmazYCortez-PintoHOliveiraCPBedossaPAdamsLAZhengMHFouadYChanWKMendez-SanchezNAhnSHCasteraLBugianesiERatziuVGeorgeJ.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202–9
43.
ZengXYuanXCaiQTangCGaoJ.Circular RNA as an epigenetic regulator in chronic liver diseases.Cells2021;10:1945
44.
AfonsoMBRodriguesPMSimãoALCastroRE.Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma.J Clin Med2016;5:30
45.
ZhangLWangZ.Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B.Virol J2020;17:40
FriedmanSLPinzaniM.Hepatic fibrosis 2022: unmet needs and a blueprint for the future.Hepatology2022;75:473–88
48.
CaballeríaLToránPCaballeríaJ.Markers of hepatic fibrosis.Med Clin (Barc)2018;150:310–6
49.
ShangLHosseiniMLiuXKisselevaTBrennerDA.Human hepatic stellate cell isolation and characterization.J Gastroenterol2018;53:6–17
50.
Altamirano-BarreraABarranco-FragosoBMéndez-SánchezN.Management strategies for liver fibrosis.Ann Hepatol2017;16:48–56
51.
MounajjedTGrahamRPSandersonSOSmyrkTC.Clinical associations of hepatic stellate cell (HSC) hyperplasia.Virchows Arch2014;465: 57–65
52.
SeoHYLeeSHLeeJHKangYNChoiYKHwangJSParkKGJangBKKimMK.Clusterin attenuates hepatic fibrosis by inhibiting hepatic stellate cell activation and downregulating the Smad3 signaling pathway.Cells2019;8:1442
53.
ZhangLMabwiHAPalangeNJJiaRMaJBahFBSahRKLiDWangDBahFBTogoJJinHBanLFengXZhengY.Expression patterns and potential biological roles of Dip2a.PLoS ONE2015;10: e0143284
54.
DewidarBMeyerCDooleySMeindl-BeinkerAN.TGF-beta in hepatic stellate cell activation and liver fibrogenesis—updated 2019.Cells2019;8:1419
55.
LiuRMDesaiLP.Reciprocal regulation of TGF-beta and reactive oxygen species: a perverse cycle for fibrosis.Redox Biol2015;6:565–77
56.
XuFLiuCZhouDZhangL.TGF-beta/SMAD pathway and its regulation in hepatic fibrosis.J Histochem Cytochem2016;64:157–67
57.
XuXYDuYLiuXRenYDongYXuHYShiJSJiangDXuXLiLXuZHGengY.Targeting follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice.Cell Commun Signal2020;18:151
58.
AndreichenkoINTsitrinaAAFokinAVGabdulkhakovaAIMaltsevDIPerelmanGSBulgakovaEVKulikovAMMikaelyanASKotelevtsevYV.4-methylumbelliferone prevents liver fibrosis by affecting hyaluronan deposition, FSTL1 expression and cell localization.Int J Mol Sci2019;20:6301
59.
RaoJWangHNiMWangZWangZWeiSLiuMWangPQiuJZhangLWuCShenHWangXChengFLuL.FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2.Gut2022;71:2539–50
WangFSFanJGZhangZGaoBWangHY.The global burden of liver disease: the major impact of China.Hepatology2014;60:2099–108
62.
ChenZXieHHuMHuangTHuYSangNZhaoY.Recent progress in treatment of hepatocellular carcinoma.Am J Cancer Res2020;10:2993–3036
63.
YangWWuYWangCLiuZXuMZhengX.FSTL1 contributes to tumor progression via attenuating apoptosis in a AKT/GSK-3β–dependent manner in hepatocellular carcinoma.Cancer Biomark2017; 20:75–85
64.
LohJJLiTWZhouLWongTLLiuXMaVWSLoCMManKLeeTKNingWTongMMaS.FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness.Cancer Res2021;81:5692–705
65.
HigashiTFriedmanSLHoshidaY.Hepatic stellate cells as key target in liver fibrosis.Adv Drug Deliv Rev2017;121:27–42
66.
ChenXSongE.Turning foes to friends: targeting cancer-associated fibroblasts.Nat Rev Drug Discov2019;18:99–115
67.
BaglieriJBrennerDAKisselevaT.The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma.Int J Mol Sci2019;20:1723
68.
MichalopoulosGKBhushanB.Liver regeneration: biological and pathological mechanisms and implications.Nat Rev Gastroenterol Hepatol2021;18:40–55
